Table 4.

Abnormal results of LA-sensitive aPTT depending on anticoagulant treatment.

Anticoagulant	Proportion of patients with abnormalities in the LA-sensitive aPTT, n
	Controls	aPLneg	aPLlow	aPLhigh
None or discontinued	3% (47)	2% (19)	5% (9)	15% (11)
Rivaroxaban	–	2% (9)	5% (5)	54% (20)*
Apixaban	–	7% (7)	0% (0)	20% (3)
VKA	–	3% (15)	11% (13)	26% (22)
LMWH	–	5% (12)	16% (9)	32% (11)

Patients with a prolonged LA-sensitive aPTT and a ratio of LA-sensitive aPTT/aPTT > 1.2 were considered abnormal.

LMWH, low molecular weight heparin; VKA, vitamin K antagonist.

*Significantly higher in comparison to the cohort with no or discontinued anticoagulants (P < 10^–4), calculated using the chi-squared test.